Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699557 | 0.90 | TP53 (0.47) | PTGER4ALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL6818624 | 0.85 | MMP13 (0.43) | PTGER4MMP13 | |
| SCHEMBL6699803 | 0.78 | PTGER4 (0.48) | PTGER4NR1H4EPHX2ALDH1A1MMP13 | |
| SCHEMBL6703233 | 0.77 | MMP13 (0.39) | PTGER4ALDH1A1MMP13MEN1KMT2A | |
| SCHEMBL6702349 | 0.76 | CLPP (0.35) | ALDH1A1 | |
| SCHEMBL6698728 | 0.73 | PTGER4 (0.47) | PTGER4NR1H4EPHX2ALDH1A1MMP13 | |
| SCHEMBL6700597 | 0.72 | KDM4E (0.50) | PTGER4NR1H4EPHX2ALDH1A1MMP13 | |
| SCHEMBL6818720 | 0.72 | PTGER4 (0.50) | PTGER4MMP13 | |
| SCHEMBL6702617 | 0.71 | MMP13 (0.41) | PTGER4ALDH1A1MMP13 | |
| SCHEMBL6704350 | 0.69 | MMP13 (0.58) | PTGER4MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885NR1H4 2045/4885EPHX2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.